ERBB2 and breast cancer: At the last follow-up (18 months post-delivery), the mother showed no signs of recurrence, and the child exhibited normal growth and neurodevelopment.<h4>Conclusions</h4>This case demonstrates that with careful multidisciplinary planning and individualized treatment strategies, it is feasible to achieve both successful maternal oncologic control and the delivery of a healthy baby in patients with HER-2 overexpressing breast cancer during pregnancy.